Targeting iHSP 70 in vitiligo: a critical step for cure?
The group of Caroline Le Poole has produced a series of elegant papers suggesting an innovative rationale for the treatment of vitiligo by limiting native iHSP70 expression, with subsequent blockade of DC activation and melanocyte loss via T-cell-specific autoimmune responses. The proof of concept was made in a mouse model of the use of a mutant iHSP70 blunting this response. The comment emphasizes that in vitiligo, a skin and possibly epidermal defect underlies the initial steps leading to inflammation and subsequent melanocyte demise and discusses the relevance of targeting iHSP in this context.
Department of Dermatology and Pediatric Dermatology, Bordeaux University Hospitals, INSERM 1035, University of Bordeaux, Bordeaux, France. alain.taieb@chu-bordeaux.fr
Alain
A
Taïeb
Julien
J
Seneschal
D001327:Autoimmune Diseases / Q000276:immunology*; D018840:HSP70 Heat-Shock Proteins / Q000276:immunology*; D006801:Humans; D014820:Vitiligo / Q000276:immunology*
D018840:HSP70 Heat-Shock Proteins
mouse models; vitiligo